Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Westminster Kingsway College Launches New Access To Higher Education Programme In Pharmacy And Biomedical Sciences
Westminster Kingsway College has launched a new Access to Higher Education programme in Pharmacy and Biomedical Sciences at its new King"s Cross Centre in central London. The College is already a leading provider of Access to Higher Education courses in London as well as specialising in courses for Pharmacy Technicians in conjunction with the University of London"s School of Pharmacy and Birkbeck College.
generic viagra online
Smoke-free Mumbai Sticker Campaign
Sticker campaign builds awareness for smoke-free Mumbai
News of the day
Prize Winning Research Could Bring Relief To 3.5 Million Denture Stomatitis (Oral Thrush) Sufferers
A research project, which has the potential to bring relief to the estimated 3.5 million UK sufferers of oral thrush, has won the ÷£25,000 Armourers & Brasiers Venture Prize. This will allow the project to proceed to clinical evaluation.
Endocrinology

LATITUDE Pharmaceuticals Initiates Two More Collaboration Studies For Its PG Depot

LATITUDE Pharmaceuticals, Inc. (LPI), a San Diego-based drug formulation developer, announced today that it has initiated two new collaboration programs for its Phospholipid Gel (PG) Depot drug delivery platform. The programs are designed to provide prolonged and peak-free pharmacokinetic profiles for 3 and 7 days following a subcutaneous injection for an antibiotic and a protein drug, respectively. The new studies bring the total to seven feasibility/license agreements that are applying the PG Depot to deliver small molecules, peptides, and proteins for pain, metabolic disease, anti-bacterial, and cardiovascular applications. Andrew Chen, PhD, LPI"s president, noted, "Our newest feasibility studies represent a growing validation of our PG Depot technology. Like our ongoing collaborations, the new programs aim to transform a cumbersome routine of multiple injections each day into a convenient once-daily or once-weekly format. Both pharma and biotech companies definitely see high value in simplifying parenteral drug administration and extending or resurrecting IP protection through novel delivery technology. The protein-friendly nature of the PG Depot will create many opportunities to convert biologics from daily to weekly injections." About PG Depot LPI"s proprietary PG Depot technology is a versatile parenteral drug delivery platform for small molecules and biological therapeutics that delivers 1-7 days of low burst, peak-free sustained drug release following a subcutaneous or intramuscular injection. The PG Depot is provided as a single-phase, ready-to-use, self-administration-capable gel that is injectable through fine (27G or smaller) needles. The gel is compatible with hydrophilic and hydrophobic small molecule drugs as well as peptides and proteins and can be manufactured using conventional processes. Because it is composed of FDA-approved injectable and biodegradable ingredients, the PG Depot has key advantages over other depot systems, which use new polymers or animal-derived materials and face ever-increasing safety hurdles at the FDA and other regulatory agencies. LATITUDE Pharmaceuticals, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009